MyTACTIC: Afficacy and safety of atezolizumab (atezo) plus chemotherapy (chemo) in patients (pts) with advanced unresectable/metastatic solid tumors with high tumor mutational burden (TMB-H) or high microsatellite instability (MSI-H)/deficient mismatch repair (dMMR)

被引：0

作者：

Spigel, David R.

Hussein, Maen A.

Zuniga, Richard

Mahadevan, Daruka

Winn, Robert

Darbonne, Walter C.

Yoo, Bongin

Kim, Young

Whitehead, Zach

Vanderwalde, Ari M.

机构：

[1] Sarah Cannon Res Inst, Dept Thorac Med Oncol, Tennessee Oncol, Nashville, TN USA

[2] Florida Canc Specialists Sarah Cannon Res Inst, Leesburg, FL USA

[3] OneOncol Inc, Precis Med, Nashville, TN USA

[4] New York Canc & Blood Specialists, Port Jefferson Stn, NY USA

[5] Univ Texas Hlth San Antonio MD Anderson Canc Ctr, Div Hematol & Med Oncol, Mays Canc Ctr, San Antonio, TX USA

[6] Virginia Commonwealth Univ, Dept Hlth Behav & Policy, Richmond, VA USA

[7] Genentech Inc, US Med Affairs Oncol, South San Francisco, CA USA

[8] Caris Life Sci, West Canc Ctr & Res Inst, Germantown, TN USA

来源：

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

2612

引用

页数：1